Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson's disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson's. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications. Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/24/20 | $38,000,000 | Series A |
AbbVie Biotech Ventures Alexandria Venture Investments Dementia Discovery Fund Mission Holdings Sofinnova Ventures | undisclosed |
